Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor
AssigneeBoehringer Ingelheim International GmbH
InventorsJuergen Daemmgen, Joanne van Ryn, Brian Guth, Michel Pairet
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor. In addition a method of treating cyclooxygenase dependent disorders, including inflammation, pain and/or rheumatic diseases, and/or neoplasia is described.
Claims20
A pharmaceutical composition comprising a first active ingredient, wherein the first active ingredient is a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and a second active ingredient, wherein the second active ingredient is a COX-2 inhibitor.
A method of minimizing the incidence of adverse thromboembolic or cardiovascular events in an individual to whom a COX-2 inhibitor has been administered comprising administering to said individual a pharmaceutical composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor.
A method of treating a cyclooxygenase dependent disorder, comprising administering to an individual in need of such treatment a pharmaceutical composition comprising a first active ingredient, wherein the first active ingredient is a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and a second active ingredient, wherein the second active ingredient is a COX-2 inhibitor.
A kit comprising
- (a) a first containment containing a pharmaceutical composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and at least one pharmaceutically acceptable carrier, and
- (b) a second containment containing a pharmaceutical composition comprising a COX-2 inhibitor and at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.